Veterans who received the updated 2024-2025 COVID-19 vaccine faced sharply lower odds of major heart trouble. The protection held even against events not obviously tied to infection. And the numbers tell a consistent story across massive datasets.
More than 1 million patients in the U.S. Department of Veterans Affairs health system provided the latest evidence. Researchers tracked outcomes for eight months. Those who got the COVID shot alongside their flu vaccine saw a 38 percent drop in COVID-associated major adverse cardiovascular events. The composite included cardiovascular death, heart attack, stroke and heart failure hospitalization.
The absolute benefit looked modest at first glance. Rates fell from about 5 events per 10,000 people to 3 per 10,000. But scale it up. In a population of 1 million, that change averts thousands of serious incidents. Protection proved strongest among adults older than 75 and those with chronic conditions such as kidney or lung disease.
Surprise arrived in the all-cause results. Vaccination linked to a nearly 24 percent reduction in broader cardiac events, not just those with confirmed COVID diagnoses. Deaths fell too. Ziyad Al-Aly, the study’s lead author at VA St. Louis Health Care System, pointed to undetected infections. “What that really means is that those [events] are actually likely related to SARS-CoV-2, that were never recognized to be so in the first place,” he said, according to STAT News.
Al-Aly emphasized the virus still circulates widely. “Despite the fact that the virus has evolved and things have mellowed down, and we no longer think of Covid infection as consequential, there is still actually a tidal wave of SARS-CoV-2 that continues to circulate in the population,” he told STAT. Much of it goes untested. Much of it triggers heart problems without clear attribution.
The findings, published June 15, 2026 in JAMA Internal Medicine, add to a growing body of large-scale research. They arrive at a moment when vaccine uptake lags. Fewer than half of older adults get the annual COVID shot, even though flu vaccination rates run higher.
Robert Califf, former FDA commissioner, wrote an accompanying editorial. He highlighted the favorable balance of benefits to risks and criticized politicization of the shots. “There are many, many studies now that show that vaccinations of various types seem to reduce the risk of chronic diseases, including cardiovascular disease,” Califf said in STAT News. This work fits the pattern.
Earlier analyses reached similar conclusions. A Cambridge-led study of nearly 46 million adults in England found lower incidence of heart attacks and strokes after vaccination. Arterial thromboses dropped as much as 10 percent in weeks 13 to 24 after the first dose. Second doses brought even larger reductions. Up to 27 percent lower after AstraZeneca. Up to 20 percent after Pfizer-BioNTech. The results appeared in University of Cambridge news.
Swedish registry data told a parallel tale. Full vaccination cut risks of several severe cardiovascular outcomes linked to COVID by 20 to 30 percent. Temporary increases in some risks appeared after individual doses. Yet they did not extend to the most serious conditions. Fredrik Nyberg of the University of Gothenburg stressed the net gain. “The increases in cardiovascular risk we saw following COVID-19 vaccination are temporary, and do not apply to the more severe conditions,” he said in a release covered by CIDRAP.
Infection itself drives far higher cardiac danger. CDC data from 40 health systems showed the risk of myocarditis, pericarditis or related complications ran many times greater after SARS-CoV-2 than after mRNA vaccination. For males ages 12 to 17, infection carried 1.8 to 5.6 times the risk compared with the second vaccine dose. The pattern held across sexes and age groups. The report ran in CDC Morbidity and Mortality Weekly Report.
Stanford Medicine researchers clarified the mechanism behind rare vaccine-linked myocarditis. Their work, published in late 2025, showed why mRNA shots trigger heart inflammation in some young males and adolescents. Yet they also underscored that COVID infection causes myocarditis at roughly 10 times the rate. Joseph Wu, director of the Stanford Cardiovascular Institute, put the trade-off plainly. “The mRNA vaccines have done a tremendous job mitigating the COVID pandemic,” he said in Stanford Medicine news. “Without these vaccines, more people would have gotten sick, more people would have had severe effects and more people would have died. But COVID’s worse.”
Patients with existing heart failure gain clear benefit too. Vaccination correlated with 82 percent lower all-cause mortality in one analysis presented at a European Society of Cardiology congress. It also cut heart failure hospitalizations and COVID infections. The data came from ESC press release.
But concerns about myocarditis and pericarditis persist in public discussion. Observational studies confirm these events remain rare after vaccination. They occur most often in adolescent and young adult males within a week of the second mRNA dose. Cases after Novavax have also been noted. Yet outcomes tend to be milder than infection-related myocarditis. Hospitalization rates stay low. Long-term complications appear uncommon. A French cohort found better 18-month results for vaccine-associated cases than for conventional myocarditis. Pfizer summarized such evidence in its own company announcement.
Recent reviews reinforce the pattern. A 2025 study in older adults with coronary disease or heart failure showed dose-dependent drops in mortality and heart failure admissions after vaccination. Revaccination data for those with prior mild cardiac events suggest it can be considered, though caution applies for confirmed myopericarditis. One Canadian analysis found vaccinated younger adults 43 percent less likely to experience sudden cardiac death.
The VA cohort had limits. Participants were mostly older, White and male. Results may not translate perfectly to younger people or other demographics. Still, the consistency across countries, health systems and years builds confidence. From England’s 46 million to Sweden’s nationwide registries to America’s veterans, the signal repeats. Vaccination lowers severe cardiovascular outcomes tied to COVID. It appears to blunt some events that might otherwise go unlinked to the virus.
Public health leaders continue to recommend updated shots for high-risk groups. The absolute risk of vaccine-related heart inflammation stays low. The risk from infection runs higher and lasts longer. Data from children and adolescents echo the adult findings. Infection triggers more frequent and prolonged vascular and inflammatory issues.
So the picture sharpens. COVID-19 vaccines do not eliminate every cardiac risk. They do reduce the most serious ones. They do so in ways that accumulate across large populations. And they do it while the virus keeps circulating, often unnoticed. That combination explains why protection against heart problems endures even as formulations update and immunity wanes. The latest VA analysis simply adds contemporary weight to an evidence base that has grown steadily since the first mRNA doses rolled out.
Clinicians now weigh these figures when counseling patients. Older adults and those with comorbidities see the clearest gains. Yet the broader reduction in all-cause events suggests wider relevance. Undiagnosed infections likely play a larger role in cardiac morbidity than many realize. Vaccination interrupts that pathway.
Questions remain about optimal timing, future variants and long-term trends in myocarditis rates. Post-pandemic hospital data show myocarditis cases stayed elevated but shifted toward older patients with comorbidities. Vaccine-associated cases appear unlikely to explain the bulk of admissions. The net effect still favors protection.
Health systems track uptake closely. Low COVID vaccination rates among older adults stand in contrast to higher flu shot numbers. The VA study and its contemporaries offer fresh ammunition for campaigns. Clear data. Quantified benefits. Real-world scale. The heart protection story has evolved from early safety signals to sustained population-level gains. And it continues.
WebProNews is an iEntry Publication